Neuroprotection of phytic acid in Parkinson’s and Alzheimer’s disease

• Published in: Journal of functional foods 2023-11, Vol.110, p.105856, Article 105856
• Main Authors: Chen, Yujie, Yuan, Wuke, Xu, Qi, Reddy, Manju B.
• Format: Article
• Language: English
• Subjects: Alzheimer’s disease; Neuroprotection; Parkinson’s disease; Phytic acid
• ISSN: 1756-4646; 2214-9414
• DOI: 10.1016/j.jff.2023.105856

[Display omitted] •IP6 exerts antioxidant, anti-amyloidβ and metal-chelating effects in PD and AD.•The bioavailability and its ability to cross blood brain barrier are low.•The theraputic efficacy of IP6 in humans is not clear. Parkinson’s disease (PD) and Alzheimer’s disease (AD) are two of the most common neurodegenerative disorders, characterized by the progressive loss of neurons. These two diseases share common molecular mechanisms, including brain iron accumulation, oxidative stress, protein aggregation, and neuroinflammation. There is no effective therapy to halt the progression of PD or AD. However, accumulating evidence suggests that the consumption of phytochemicals may delay the onset or slow down the progression of neurodegeneration. Phytic acid, is a dihydrogenphosphate ester of inositol. It is stored as phosphorus in plant seeds like cereals, legumes, and nuts. Traditionally, IP6 has been considered an anti-nutritional factor due to its mineral chelating properties, which can reduce mineral absorption. Recent research also indicates its potential benefits for neurodegenerative disorders. In this review, we will summarize the sources and bioavailability of IP6 and its potential neuroprotective roles in preventing or slowing down the progression of PD and AD.